Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.65 |
| ▸ | JUN | P05412 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606219 | 0.94 | NFE2L2 (0.62) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL11928814 | 0.92 | HDAC1 (0.68) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL11928824 | 0.92 | HDAC1 (0.68) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL16382601 | 0.90 | NFKB1 (0.80) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL2743877 | 0.89 | NFKB1 (0.79) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL30493821 | 0.89 | NFKB1 (0.79) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL2743876 | 0.89 | NFKB1 (0.79) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL9907028 | 0.88 | NFE2L2 (0.62) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL9972320 | 0.86 | HDAC1 (0.67) | NFE2L2NFKB1JUNKDM4EALDH1A1 | |
| SCHEMBL13358184 | 0.86 | HDAC1 (0.67) | NFE2L2NFKB1JUNKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | NFE2L2 1264/4885NFKB1 1410/4885JUN 1899/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885NFKB1 418/4885JUN 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.